Stocktoria
Immix Biopharma, Inc. IMMX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-12-16
Chart by TradingView
3/9
Piotroski F — financial health
9.45
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$30.0M | -$22.7M | -$16.1M | -$8.2M | -$1.4M |
| Net income | -$29.4M | -$21.6M | -$15.4M | -$8.2M | -$24.4M |
| Operating cash flow | -$23.9M | -$14.6M | -$11.4M | -$7.4M | -$1.6M |
| Free cash flow | -$24.7M | -$15.8M | -$11.4M | — | -$1.6M |
| Total assets | $104.8M | $22.9M | $19.9M | $14.9M | $18.2M |
| Total liabilities | $11.0M | $9.7M | $3.7M | $1.7M | $202,039 |
| Shareholders' equity | $93.8M | $13.3M | $16.2M | $13.2M | $18.0M |
| Ratios | |||||
| Return on assets | -28.0% | -94.2% | -77.4% | -55.2% | -134.0% |
| Return on equity | -31.3% | -163.1% | -95.2% | -62.5% | -135.5% |
| Current ratio | 10.01 | 2.33 | 5.32 | 11.70 | 90.01 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 9.45 (safe)
- Working capital / assets 0.869
- Retained earnings / assets -0.996
- EBIT / assets -0.286
- Equity / liabilities 8.493
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001873835 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.